Pharmaceutical

FDA fast tracks Mendus’s acute myeloid leukaemia vaccine vividencel

The company expects a further survival readout in Q4 2023, with plans for a second Phase II trial set for H2 2023.

Sep 9, 2023 - 20:00
FDA fast tracks Mendus’s acute myeloid leukaemia vaccine vividencel
The company expects a further survival readout in Q4 2023, with plans for a second Phase II trial set for H2 2023.
Read the original article

Tags:

Previous Article

Hope for the UK clinical trial landscape but it requires a lot of work

Next Article

Eloxx moves ahead with plans with gene therapy for rare kidney disorder

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bayer’s not breaking up. At least not yet

Bayer’s not breaking up. At least not yet

Mar 6, 2024

Janssen submits sBLA to FDA for NSCLC combination therapy

Janssen submits sBLA to FDA for NSCLC combination therapy

Aug 28, 2023

STAT+: Epic and Microsoft’s AI collaboration, Amazon and 3M, & Abbott’s CGM momentum

STAT+: Epic and Microsoft’s AI collaboration, Amazon an...

Apr 23, 2023